Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026)
Vireo Growth (VREOF) reported Return on Capital Employed of 0.91% for Q1 2026, down 679.0% on a YoY basis from 0.16% in Q1 2025, and up 593.95% sequentially from 0.18% in Q4 2025.
Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Return on Capital Employed data on file, last reported at 0.91% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 679.0% year-over-year to 0.91%; the trailing twelve-month figure through Mar 2026 stood at 0.91% (down 679.0% YoY), and the FY2025 full-year result was 0.29%, down 1448.0% from the prior year.
- Return on Capital Employed advanced to 0.91% in Q1 2026, from 0.18% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 527.87% in Q1 2024 to a low of 528.74% in Q4 2023.
- A 5-year average of 31.89% and a median of 0.91% in 2026 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 52365 bps in 2023 and soared 54218 bps in 2024, its largest moves.
- Tracing VREOF's Return on Capital Employed over 5 years: stood at 5.08% in 2022, then tumbled by 10303 bps to 528.74% in 2023, then soared by 103 bps to 13.44% in 2024, then slumped by 101 bps to 0.18% in 2025, then soared by 594 bps to 0.91% in 2026.
- Business Quant data shows VREOF's Return on Capital Employed at 0.91% in Q1 2026, 0.18% in Q4 2025, and 0.01% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 0.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.91% |
| Dec 31, 2025 | -0.18% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | 1.33% |
| Mar 31, 2025 | 7.70% |
| Dec 31, 2024 | 13.44% |
| Sep 30, 2024 | 30.21% |
| Jun 30, 2024 | 362.84% |
| Mar 31, 2024 | 527.87% |
| Dec 31, 2023 | -528.74% |
| Sep 30, 2023 | 173.96% |
| Jun 30, 2023 | -3.04% |
| Mar 31, 2023 | 1.87% |
| Dec 31, 2022 | -5.08% |
| Sep 30, 2022 | -10.99% |
| Jun 30, 2022 | -13.57% |
| Mar 31, 2022 | -16.32% |
| Dec 31, 2021 | -13.73% |
| Sep 30, 2021 | -11.73% |
| Jun 30, 2021 | -12.35% |